PRECISION MEDICINE IN ONCOLOGY: A PROFESSIONAL GUIDE TO ANALYTICS, LIQUID BIOPSY PROTOCOLS AND TARGET TREATMENT FRAMEWORKS

Cancer is no longer defined by where it starts. It is defined by what drives it — and how precisely we can act on that knowledge. Precision Medicine in Oncology: The Advanced Clinical Textbook is a comprehensive, specialist-level clinical reference written for the oncologist, molecular pathologist, clinical geneticist, and advanced practitioner who demands more than a general overview. This is the textbook for professionals who read genomic profiling reports, interpret liquid biopsy results, navigate biomarker-matched therapy decisions, and manage the resistance mechanisms that arise when targeted agents inevitably meet the evolutionary resilience of cancer. Spanning fifteen chapters and more than 570 pages, this textbook covers the full clinical scope of precision oncology — from molecular foundations to cutting-edge therapeutic delivery systems — organized across five thematic parts: Part I — Foundations establishes the molecular basis of cancer biology, the hallmarks of malignancy, and the conceptual framework of precision medicine from its cytogenetic origins to the tumor-agnostic regulatory era. Part II — Biomarker Analytics provides a rigorous treatment of genomic, transcriptomic, proteomic, and epigenomic profiling — including comprehensive NGS platforms, PD-L1 and companion diagnostic assay interpretation, mutational signature analysis, and emerging multi-omic integration strategies. Part III — Liquid Biopsy Protocols delivers a complete clinical framework for circulating tumor DNA analysis, circulating tumor cell isolation, exosomal biomarker profiling, and the application of liquid biopsy across early detection, minimal residual disease monitoring, treatment response assessment, and resistance profiling. Part IV — Targeted Treatment Frameworks examines the mechanistic basis and clinical protocols of targeted kinase inhibitors, immune checkpoint inhibition with biomarker-driven patient selection, antibody-drug conjugates, radioligand therapy, CAR-T cell therapy, and the composite predictive biomarkers — TMB, MSI, and HRD — that govern their use. Part V — Clinical Application and Future Directions addresses multidisciplinary tumor board integration of molecular data, the ethical and regulatory dimensions of genomic medicine, and the convergence of artificial intelligence and real-world evidence in shaping the next generation of precision cancer care. Inside this textbook, you will find: Structured clinical interpretation frameworks for NGS reports, ctDNA results, PD-L1 IHC, and composite biomarkers Detailed resistance mechanism profiles for EGFR, ALK, BRAF, KRAS, BCR-ABL1, CDK4/6, and HER2-directed agents — with ctDNA-guided next-line therapy strategies The complete PD-L1 assay landscape: four antibody clones, three scoring systems, and the critical distinction between TPS, CPS, and IC scoring across drug-tumor combinations A tumor-type-specific liquid biopsy application guide spanning MRD detection, companion diagnostic use, on-treatment monitoring, resistance profiling, and recurrence surveillance Comprehensive ADC engineering and clinical profiles for trastuzumab deruxtecan, sacituzumab govitecan, enfortumab vedotin, mirvetuximab soravtansine, and the expanding approved ADC portfolio Evidence-graded biomarker tables, clinical decision algorithms, landmark trial data, and FDA companion diagnostic references throughout It meets the specialist at the level of practice — where molecular complexity is the daily reality, where the right biomarker interpretation changes lives, and where the standard of care is advancing faster than any single clinician can track without a comprehensive, current, and clinically authoritative reference.